Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05067634




Registration number
NCT05067634
Ethics application status
Date submitted
14/09/2021
Date registered
5/10/2021
Date last updated
31/01/2024

Titles & IDs
Public title
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Scientific title
Open-Label Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Secondary ID [1] 0 0
YKP3089C040
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Partial Epilepsy 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Xcopri

Experimental: 12 to < 18 year olds -

Experimental: 6 to <12 years old -

Experimental: 4 to <6 years old -

Experimental: 2 to <4 years old -


Treatment: Drugs: Xcopri
Age groups 12 to <18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to <12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to <6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to <4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Adverse Events and SAEs
Timepoint [1] 0 0
3 Years
Secondary outcome [1] 0 0
To collect plasma samples of cenobamate to support the evaluation of the pharmacokinetics of cenobamate tablets and suspension in pediatric subjects with partial onset (focal) seizures
Timepoint [1] 0 0
3 Years
Secondary outcome [2] 0 0
Acceptability and palatability assessment (determined by a 5-point Hedonic Scale) of the oral formulation and tablets
Timepoint [2] 0 0
3 Years

Eligibility
Key inclusion criteria
1. Have a diagnosis of epilepsy with partial-onset (focal) seizures (POS) with or without
secondarily generalized seizures according to the International League Against
Epilepsy's (ILAE) Classification of Epileptic Seizures. A diagnosis should have been
established at least 12 months prior to Visit 1 (Screening) by clinical history and an
electroencephalogram (EEG) that is consistent with the diagnosis; normal interictal
EEGs will be allowed provided that the participant meets the other diagnosis criterion
(i.e., clinical history)

2. Male or female participant, from age 2 to less than 18 years at the time of informed
consent/assent (dates including informed consent in YKP3089C039)

3. Have a minimum weight of 10.0 kilograms (kg) (22.0 pounds [lb])

4. Have had a brain imaging (e.g., magnetic resonance imaging [MRI] scan or computed
tomography (CT) within 10 years before Visit 1 (Screening) that ruled out a
progressive cause of epilepsy.

5. For subjects new to Study YKP3089C040, participants must have had at least 1 POS
seizure during the 28-day Baseline Period. Only simple POS with motor signs, complex
POS, and complex POS with secondary generalization are counted toward this inclusion
for POS

6. Are currently being treated with stable doses of 1 to a maximum of 3 approved
antiepileptic drugs (AEDs). Doses must be stable for at least 4 weeks before to Visit
1 (Screening). A vagal nerve stimulator [VNS] will not be counted as one of the 3
allowed AEDs but the settings should be stable for at least 4 weeks prior to Visit 1
(Screening).

7. Investigator believes subject could benefit from new or continued exposure to study
drug

8. Subjects entering from study YKP3089C039 must continue to meet all of the inclusion
criteria from the YKP3089C039 study

9. Subjects receiving felbamate as a concomitant AED must meet the following criteria:

1. Have a 12-month history of felbamate use and a history of a fixed dosing regimen
for a minimum of 60 days prior to Visit 1 (Screening).

2. No prior or known history of hepatotoxicity or hematologic disorder due to
felbamate.

10. Subjects following a ketogenic diet will be allowed as long as the diet has been
stable for at least 30 days prior to Visit 1 (Screening) and will remain stable for
the duration of the study
Minimum age
2 Years
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Females who are breastfeeding or pregnant at Screening or Baseline.

2. Current or history of pseudo-seizures (psychogenic nonepileptic seizures) within
approximately 2 years before Visit 1 (Screening).

3. Have a history of status epilepticus that required hospitalization during the 6 months
before Visit 1 (Screening).

4. Have an unstable psychiatric diagnosis that may confound participants' ability to
participate in the study or that may prevent completion of the protocol-specified
tests (e.g., significant suicide risk, including suicidal behavior and ideation within
6 months before Visit 1 (Screening), current psychotic disorder, acute mania).

5. Any suicidal ideation with intent, with or without a plan within 6 months before Visit
2 [i.e., answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the
Columbia-Suicide Severity Rating Scale (C-SSRS) in participants aged 6 and above, if
able].

6. Are scheduled and/or confirmed to have epilepsy surgery within 6 months after Visit 1
(Screening); however, those who have previously documented "failed" epilepsy surgery
will be allowed.

7. Evidence of clinically significant disease (e.g., cardiac, respiratory,
gastrointestinal, renal disease) that in the opinion of the investigator(s) could
affect the participant's safety or interfere with the study assessments.

8. Presence of only nonmotor simple partial seizures or primary generalized epilepsies.

9. Evidence of moderate or severe renal insufficiency as defined by estimated glomerular
filtration rates (eGFRs) of 31 to < 60 "milliliters per minute (mL/min)" and < 30
mL/min, respectively.

10. Evidence of significant active hepatic disease. Stable elevation of liver enzymes,
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) due to concomitant
medication(s), will be allowed if they are less than 3 times the upper limit of normal
(ULN).

11. Evidence of significant active hematological disease; white blood cell (WBC) count
equal or less than 2500/µL (2.50 1E+09/liter [L]) or an absolute neutrophil count
equal or less than 1000/µL (1.00 1E+09/L).

12. Subjects with Familial short QT syndrome.

13. Clinically significant electrocardiogram (ECG) abnormality, including prolonged
corrected QT interval (QTc) defined as greater than 450 milliseconds (msec) or
shortened corrected QT interval (QTc) defined as less than 340 msec.

14. Have a progressive central nervous system (CNS) disease, including degenerative CNS
diseases and progressive tumors.

15. Subject has a history of any serious drug-induced hypersensitivity reaction
(including, but not limited to, Stevens Johnson syndrome, toxic epidermal necrolysis,
or DRESS) or any drug-related rash requiring hospitalization.

16. History of AED-associated rash that involved conjunctiva or mucosae.

17. History of more than one non-serious drug-related hypersensitivity reaction that
required discontinuation of the medication.

18. Concomitant use of vigabatrin. Participants who took vigabatrin in the past must be
off vigabatrin for at least 5 months before Visit 1 (Screening) and with documentation
showing no evidence of a vigabatrin-associated clinically significant abnormality in a
visual perimetry test.

19. A history of intermittent use of rescue benzodiazepines (i.e., 1 to 2 doses over a
24-hour period is considered a 1-time rescue) more than once within the 30 days prior
to Visit 1(Screening).

20. A VNS implanted less than 5 months before Visit 1 (Screening) or changes in parameter
less than 4 weeks before Visit 1 (or thereafter during the study).

21. History of or a concomitant medical condition that in the opinion of the
investigator(s) would preclude the participant's participation in a clinical study or
compromise the participant's ability to safely complete the study.

22. Have participated in a study involving administration of an investigational drug or
device within 4 weeks before Visit 1 (Screening), or within approximately 5 half-lives
of the previous investigational compound, whichever is longer.

23. Participants with rare hereditary problems of galactose intolerance, the Lapp lactase
deficiency or glucose-galactose malabsorption.

24. For subjects new to Study YKP3089C040 previous exposure to cenobamate or
sensitivity/allergy to components of the oral suspension.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/01/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2026
Actual
Sample size
Target
140
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Austin Health - Heidelberg
Recruitment hospital [2] 0 0
Royal Children's Hospital Melbourne - Parkville
Recruitment hospital [3] 0 0
Sydney Children's Hospital - Randwick - Randwick
Recruitment hospital [4] 0 0
Children's Health Queensland Hospital and Health Service - South Brisbane
Recruitment postcode(s) [1] 0 0
- Heidelberg
Recruitment postcode(s) [2] 0 0
- Parkville
Recruitment postcode(s) [3] 0 0
- Randwick
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
Germany
State/province [18] 0 0
Berlin
Country [19] 0 0
Germany
State/province [19] 0 0
Kehl
Country [20] 0 0
Germany
State/province [20] 0 0
Kiel
Country [21] 0 0
Germany
State/province [21] 0 0
Munich
Country [22] 0 0
Germany
State/province [22] 0 0
Tübingen
Country [23] 0 0
Hungary
State/province [23] 0 0
Budapest
Country [24] 0 0
Hungary
State/province [24] 0 0
Debrecen
Country [25] 0 0
Korea, Republic of
State/province [25] 0 0
Cheonju
Country [26] 0 0
Korea, Republic of
State/province [26] 0 0
Seoul
Country [27] 0 0
Korea, Republic of
State/province [27] 0 0
Suwon
Country [28] 0 0
Poland
State/province [28] 0 0
Kielce
Country [29] 0 0
Poland
State/province [29] 0 0
Kraków
Country [30] 0 0
Spain
State/province [30] 0 0
Barcelona
Country [31] 0 0
Spain
State/province [31] 0 0
Madrid
Country [32] 0 0
Spain
State/province [32] 0 0
Pamplona
Country [33] 0 0
Spain
State/province [33] 0 0
Santiago De Compostela
Country [34] 0 0
Spain
State/province [34] 0 0
Sevilla

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
SK Life Science, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric
subjects 2-17 years of age with partial-onset (focal) seizures
Trial website
https://clinicaltrials.gov/ct2/show/NCT05067634
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Marc Kamin, MD
Address 0 0
SK Life Science, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Meagan Whritner
Address 0 0
Country 0 0
Phone 0 0
201-431-7812
Fax 0 0
Email 0 0
mwhritner@sklsi.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05067634